Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
123,650,000
-
Total 13F shares
-
115,139,005
-
Share change
-
+14,887,365
-
Total reported value
-
$1,492,193,870
-
Put/Call ratio
-
31%
-
Price per share
-
$12.96
-
Number of holders
-
154
-
Value change
-
+$199,142,954
-
Number of buys
-
61
-
Number of sells
-
85
Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q1 2017
As of 31 Mar 2017,
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by
154 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
115,139,005 shares.
The largest 10 holders included
Third Security, LLC, BlackRock Inc., IRIDIAN ASSET MANAGEMENT LLC/CT, VANGUARD GROUP INC, BB BIOTECH AG, First Eagle Investment Management, LLC, FMR LLC, Invesco Ltd., STATE STREET CORP, and SENZAR ASSET MANAGEMENT, LLC.
This page lists
154
institutional shareholders reporting positions in this security
for the Q1 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.